FAK (Focal adhesion kinase) Inhibitors Market: By Disease Type (Metastatic Melanoma, Leukemia, Lymphoma, Asthma, Sarcoma, Neoplasms, Fibrosis, Alzheimer’s disease, Cognitive disorders, Others ), By Molecule (Masitinib, IN10018, AZD0530, VS-6063, VS-4718, TPX-0005, GSK22560098, AMP945, AMP886, SY-707, 4SC 203, APG-2449, CEP-37440, PF-562271), By Clinical Phase (Pre-clinical, Phase 1, Phase 2, Phase 3) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

FAK (Focal adhesion kinase) Inhibitors Market was valued at USD xx in 2022 and is poised to grow at a CAGR of x.x% over 2023-2029.  A non-receptor tyrosine kinase called focal adhesion kinase (FAK) is involved in the growth, adhesion, migration, and remodeling of the tumor microenvironment (TME), as well as the advancement of most cancer types.  Early-stage clinical trials with FAK inhibitors showed them to perform effectively in preclinical settings. Furthermore, strong data suggests that targeting FAK in combination strategies is more successful at reversing the failure of chemotherapies or targeted therapies in solid tumors like metastatic melanoma, non-small cell lung cancer, and pancreatic cancer. According to the American Cancer Society, about 97,610 people will be diagnosed with melanomas in the USA, with around 4% cases of metastatic melanoma according to ASCO. Therefore, the companies are focusing on launching new products to maintain growth in the market. For instance, AB Sciences received FD approval to start phase 3 clinical trials of masitinib for the treatment of progressive multiple sclerosis. The growing prevalence of various types of cancers, greater understanding of the diagnosis, increase in government funding, rising healthcare costs, and increasing adoption of technology also heighten the overall growth of the market.

FAK (Focal adhesion kinase) Inhibitors Market Key Developments:

  • In 2021, InxMed’s IN10018 received fast-track approval from FDA for the treatment of Platinum-Resistant Recurrent Ovarian Cancer.

FAK Inhibitors Market Dynamics

The market is expected to rise as the incidence of cancer- benign and metastatic has been increasing globally Increased prevalence of cancer such as lymphomas, leukemias, sarcoma, metastatic cancer, and various neoplasms amongst the population is anticipated to grow the market over the forecasting period. Non-small cell lung cancer accounts for 81% of all the lung cancer diagnoses in the USA with an estimated 238,340 adults to be diagnosed with the same in 2023. Therefore, technological advancement, better disease diagnosis, and government screening programs to lower the incidence rate and mortality and increasing medical costs are anticipated to burgeon the growth of the FAK inhibitors market over the forecast years.

FAK Inhibitors Market Segmentation

By Disease Type
  • Metastatic Melanoma
  • Leukemia
  • Lymphoma
  • Asthma
  • Sarcoma
  • Neoplasms
  • Fibrosis
  • Alzheimer’s disease
  • Cognitive disorders
  • Others
By Molecule
  • Masitinib
  • IN10018
  • AZD0530
  • VS-6063
  • VS-4718
  • TPX-0005
  • GSK22560098
  • AMP945
  • AMP886
  • SY-707
  • 4SC 203
  • APG-2449
  • CEP-37440
  • PF-562271
By Clinical Phase
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Frequently Asked Questions

The global FAK inhibitors market was valued at USD xx in 20xx and is expected to grow at x.x% CAGR over the forecast period 20xx – 20xx.

Rising cancer incidence, improving technology with heavy R&D investments in the area are key opportunities for companies to enhance their revenue. over the forecast years

These are used for many indications including leukemias, lymphomas, metastatic melanoma, sarcoma, various types of neoplasms, fibrosis and connective and soft tissue diseases.

AB Science, AstraZeneca, Amplia Therapeutics Ltd., Cancer Therapeutics CRC, Verastem, Inc., 4SC AG, Ascentage Pharma, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Centaurus Biopharma Ltd., InxMed, Pfizer, Shouyao Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd, Zai Lab

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • AB Science (France)
  • AstraZeneca (UK)
  • Amplia Therapeutics Ltd. (Australia)
  • Cancer Therapeutics CRC (Australia)
  • Verastem, Inc. (US)
  • 4SC AG (Germany)
  • Ascentage Pharma (China)
  • Bristol-Myers Squibb company (US)
  • Boehringer Ingelheim International GmbH (Germany)
  • Centaurus Biopharma Ltd. (China)
  • InxMed (China)
  • Pfizer (US)
  • Shouyao Holdings Co. Ltd. (China)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Zai Lab (China)

Adjacent Markets